Travere Therapeutics is a biotechnology business based in the US. Travere Therapeutics shares (TVTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.25 – an increase of 2.99% over the previous week. Travere Therapeutics employs 380 staff and has a trailing 12-month revenue of around $203.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $18.25 |
|---|---|
| 52-week range | $5.12 - $20.33 |
| 50-day moving average | $16.56 |
| 200-day moving average | $10.11 |
| Wall St. target price | $26.94 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.52 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $18.25 from 2024-11-22
| 1 week (2024-11-15) | 2.99% |
|---|---|
| 1 month (2024-10-24) | 0.88% |
| 3 months (2024-08-23) | 103.23% |
| 6 months (2024-05-23) | 187.85% |
| 1 year (2023-11-22) | 219.06% |
|---|---|
| 2 years (2022-11-23) | -5.59% |
| 3 years (2021-11-23) | 29.34 |
| 5 years (2019-11-22) | 33.41% |
| Revenue TTM | $203.4 million |
|---|---|
| Gross profit TTM | $-31,354,000 |
| Return on assets TTM | -26.14% |
| Return on equity TTM | -279.94% |
| Profit margin | -172.75% |
| Book value | $-0.39 |
| Market Capitalization | $1.6 billion |
TTM: trailing 12 months
We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.
Travere Therapeutics's shares were split on a 1:9 basis on 7 November 2011 . So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.
Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $5.12 up to $20.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.7. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).
Travere Therapeutics, Inc. , a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U. S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.